BioCentury | Sep 28, 2015
Company News

University Health Network, Sernova deal

...glucose-responsive therapeutic cells to treat insulin-dependent diabetes. Sernova plans to use the cells with its Cell Pouch...
...organ-like chamber that provides microcirculation essential to the early function and long-term survival of cells. Cell Pouch...
BioCentury | Aug 17, 2015
Company News

Sernova, Massachusetts General Hospital, JDRF deal

...JDRF. The deal will incorporate an immune protectant technology developed at the hospital with Sernova’s Cell Pouch...
...project aims to improve the success of implanting pancreatic islet cells to treat the disease. Cell Pouch...
BioCentury | Oct 14, 2013
Clinical News

Cell Pouch: Phase I/II data

...Data from the first 2 patients in an open-label, Canadian Phase I/II trial showed that Cell Pouch...
...said the islet cells survived and insulin was present in the patients. Additionally, the explanted Cell Pouch...
...islet transplantation who will also receive standard immunosuppressive therapy. Sernova Corp. (TSX-V:SVA), London, Ontario Product: Cell Pouch...
BioCentury | Sep 16, 2013
Company News

Medicyte, Sernova deal

...a material transfer agreement to jointly evaluate the use of Medicyte's upcyte technology in Sernova's Cell Pouch System...
...genetically engineered primary cells that are up regulated through the introduction of proliferation genes. The Cell Pouch System...
BioCentury | May 28, 2012
Product Development

Islet defense

...Sernova Corp. is developing its Sertolin cell technology and Cell Pouch System device to provide an immune-privileged, vascularized...
...cells from immediate death and ensures sufficient oxygen is available to the cells using its Cell Pouch System...
...remain viable in the Cell Pouch System after a single transplantation. In a diabetic pig model, the Cell Pouch System...
BioCentury | May 7, 2012
Clinical News

Cell Pouch: Phase I/II started

...Sernova began an open-label, Canadian Phase I/II trial to evaluate Cell Pouch implanted 2-12 weeks before transplantation...
...islet transplantation. Patients will also receive standard immunosuppressive therapy. Sernova Corp. (TSX-V:SVA), London, Ontario Product: Cell Pouch...
BioCentury | Oct 31, 2011
Company News

Sernova, University of Alberta Hospital deal

...with the hospital's Clinical Islet Transplant Program to develop a next generation version of Sernova's Cell Pouch System...
...hospital for studies of the system and will have access to any data generated. The Cell Pouch System...
BioCentury | Mar 14, 2011
Clinical News

Sernova preclinical data

...In cynomolgus monkeys, implantation of Sernova's Cell Pouch System led to no skin irritation, inflammation or infections through...
...tissues, had "well-established" blood supplies, and formed intra-pouch cavities suitable for therapeutic cell transplantation. The Cell Pouch System...
...to the early function and long-term survival of cells. Sernova Corp. (TSX-V:SVA), London, Ontario Product: Cell Pouch System...
BioCentury | Jul 19, 2010
Clinical News

Sernova preclinical data

...Diabetic pigs receiving autologous islet cell transplantation using Sernova's Cell Pouch System device achieved long-term glucose normalization and...
...Edmonton Protocol of islet transplantation. No adverse events related to the device were observed. The Cell Pouch System...
...at the Transplantation Society meeting in Vancouver in August. Sernova Corp. (TSX-V:SVA), London, Ontario Product: Cell Pouch System...
BioCentury | Nov 9, 2009
Clinical News

Sernova preclinical data

...which were destroyed by IgG-mediated rejection at 14 days. Additionally, islet cell transplantation using Sernova's Cell Pouch System...
...modulate the immune system and can thus provide an immune-protected environment for cell transplantation. The Cell Pouch System...
...Transplant Association and the International Xenotransplantation Association in Venice. Sernova Corp. (TSX-V:SVA), London, Ontario Product: Cell Pouch System...
Items per page:
1 - 10 of 11